Interesting article reinforcing what we already know about big pharma's impending patents cliffs across a wide range of drugs.
IMO it reinforces the RAC strategy not to rush into a deal. As times progresses, and assuming our clinical results confirm the efficancy of bisantrene, the timing for a deal may well be when BP is most desperate to replenish their revenue streams.
https://finance.yahoo.com/news/pharmaceutical-industry-finds-itself-historical-164751287.html?guccounter=1
Industry news, page-1671
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.075(4.67%) |
Mkt cap ! $272.6M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.62 | $1.51 | $216.8K | 139.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 651 | $1.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 608 | 1 |
View Market Depth
| Last trade - 13.08pm 09/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |